[
    [
        {
            "time": "",
            "original_text": "BPI-3016是贝达自主研发的天然胰高血糖素样肽-1（GLP-1）类似物，拟用于糖尿病的治疗，目前该项目针对糖尿病适应症的I期临床研究正在进行中",
            "features": {
                "keywords": [
                    "贝达药业",
                    "BPI-3016",
                    "GLP-1",
                    "糖尿病",
                    "I期临床"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "BPI-3016是贝达自主研发的天然胰高血糖素样肽-1（GLP-1）类似物，拟用于糖尿病的治疗，目前该项目针对糖尿病适应症的I期临床研究正在进行中",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "公司产品埃克替尼、恩沙替尼均属于尚在专利保护期内的1类新药",
            "features": {
                "keywords": [
                    "贝达药业",
                    "埃克替尼",
                    "恩沙替尼",
                    "专利保护",
                    "1类新药"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "公司产品埃克替尼、恩沙替尼均属于尚在专利保护期内的1类新药",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        }
    ]
]